Clinical Trials
Our Clinical Trials
Endeavor BioMedicines is committed to developing therapies that change treatment expectations and restore hope for patients and their loved ones. At this time, our investigational therapies can only be accessed through participation in a clinical trial. Following is more information about Endeavor BioMedicines-sponsored clinical trials.
Taladegib (ENV-101)
Currently enrolling
The WHISTLE-PF clinical trial stands for Wound-remodeling Hedgehog-inhibitor ILD Study Testing Lung Function Endpoints. It is a Phase 2b global trial evaluating the safety and efficacy of taladegib in patients with idiopathic pulmonary fibrosis.
Our Expanded Access Policy
Endeavor BioMedicines’ goal is to provide access to our investigational therapies through ongoing clinical trials.
In general, expanded access to investigational therapies may be considered when:
- A patient has a serious disease or condition, or their life is immediately threatened by their disease or condition.
- There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition.
- Patient enrollment in a clinical trial is not possible.
- The potential patient benefit justifies the potential risks of treatment.
- Providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication.
At this time, Endeavor is not making its unapproved therapies available for new expanded access requests or on a right-to-try basis. Endeavor must ensure adequate supply of its investigational products is available for ongoing clinical trials and development programs, and therefore encourages participation in a clinical trial as the best way to access these products. You can learn more about our ongoing clinical trials by accessing information on the clinicaltrials.gov website. Consistent with the 21st Century Cures Act, Endeavor may revise this policy at any time.